ARUP's Laboratory Test Directory

Human Immunodeficiency Virus 1, Genotyping : 0055670
[ image for: Drugs and Mutation List]
Drugs and Mutation List
  


Mnemonic: HIV1GENO

Methodology: Reverse Transcription Polymerase Chain Reaction/DNA Sequencing
Performed: Tue-Sat
Reported: 5-10 days
Specimen Required: Collect:  Two 5 mL lavender (EDTA) or PPT.  Remove EDTA plasma from cells ASAP.  Centrifuge PPT plasma ASAP.

Transport:  5 mL plasma, frozen.  (Min: 2.5 mL) Submit specimen in an ARUP Standard Transport Tube.

Submit specimen according to Biological Substance, Category B, shipping guidelines.


Pediatric Collection/Transport:  

Submit specimen according to Biological Substance, Category B, shipping guidelines.


Remarks:  CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.  Remove EDTA plasma from cells ASAP and freeze in a polypropylene tube at -20°C for transport.  Spin PPT ASAP and freeze at -20°C or lower for transport.  This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 RNA copies per mL of plasma.

Unacceptable Conditions:  Serum, whole blood, or heparinized plasma.  Specimens that are thawed or have exposed to repeated freeze/thaw cycles.

Stability:  After separation from cells:  Ambient: 30 minutes; Refrigerated: 2 hours; Frozen: 4 months
Reference Interval:
By report
Interpretive Data: Test Information: HIV-1 Genotype
This assay predicts HIV-1 resistance to protease and reverse transcriptase inhibitor anti-retroviral drugs. The entire protease gene and codons 1-335 of the reverse transcriptase gene of the viral genome are sequenced at ARUP Laboratories using the Viroseq HIV-1 Genotyping System kit. Viroseq HIV-1 Genotyping software assigns drug resistance based on the sample sequence.  For the most current resistance algorithm and drug list, see the Drugs and Mutations link above.

A patient's response to therapy depends on multiple factors including the percentage of a patient's viral population that is resistant, patient compliance, access to adequate care, optimal dosing, and drug pharmacology issues, including absorption, elimination, and drug interactions. Therefore, this test should be used only in conjunction with clinical presentation and other laboratory markers (e.g., symptoms, treatment history, clinical impressions, results from other tests, etc.) when making therapeutic decisions. Results from different test methods/algorithms may provide different resistance interpretation.

This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 RNA copies per mL of plasma, as measured with the Roche Amplicor HIV-1 Monitor assay (Roche Diagnostic Systems, Branchburg, NJ). This test does not detect minor HIV-1 populations that are less than approximately 20 percent of the total population.

The ARUP HIV-1 Genotyping Assay uses the Viroseq HIV-1 Genotyping System Software to identify mutations associated with drug resistance. According to the Viroseq software manual, some insertions/deletions may be difficult to detect using this software; therefore, in rare cases, insertions/deletions in the viral sequence may result in an inaccurate drug resistance report.

The performance characteristics of this test were determined by ARUP Laboratories, Inc.
Note: Click on the link above for list of drugs included in report.
CPT Code(s): 87901
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org